{"name":"RVL Pharmaceuticals, Inc.","slug":"rvl-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"RVL Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative treatments for neurological disorders. The company's pipeline includes several drug candidates in various stages of development, with a particular emphasis on advancing therapies for conditions such as spasticity.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":49721000,"revenueGrowth":184.1,"grossMargin":81,"rdSpend":3966000,"netIncome":-51692000,"cash":128510000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"RVL-1201","genericName":"RVL-1201","slug":"rvl-1201","indication":"Presbyopia (age-related loss of accommodation)","status":"phase_3"}]}],"pipeline":[{"name":"RVL-1201","genericName":"RVL-1201","slug":"rvl-1201","phase":"phase_3","mechanism":"RVL-1201 is an alpha-1A adrenergic agonist that increases pupil dilation (mydriasis) by stimulating alpha-1A receptors on the dilator pupillae muscle.","indications":["Presbyopia (age-related loss of accommodation)","Reduced pupil size associated with presbyopia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOY3RvYXNZVGJJQldNVkpVeXE0b3hnLW9JcGY0OWJ4WnFCZk5CQkc3djhkT2h5UUhKMEx5MzJ1VHRiak1qNjg4LXV6NXNxZV9jd1ZtX3NLTVE0UXI5WUNfUnB3NzVHOVJNZ0dvbDNaU1lXcXZrVGZSYmhnVFZ1UU9SUkhCRWlVX1hiY09EaDJ2WWZYek1FWlM3V2ZYckVRN0Vf?oc=5","date":"2025-11-24","type":"trial","source":"Yahoo Finance","summary":"RVL Pharmaceuticals Announces Leadership Appointments to Accelerate Next Phase of Growth and Commercial Momentum - Yahoo Finance","headline":"RVL Pharmaceuticals Announces Leadership Appointments to Accelerate Next Phase of Growth and Commercial Momentum","sentiment":"neutral"},{"date":"2024-02-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-01-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-12-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNdEYxQTk5U2VFdkJKNXEyem1ZWkVMcHh0OGFEa0ZRc2R1UTE3bm9uR2h3RVZ1aHJkMGV6d3hnQ0V0Nk5Bcl9fUmwxVEJoZDUwSXZaZ29tcENrbFRSOGJ1NENGYWNDSUU2U3B4UjBTckktcVlwUWthTXN0OE9PMkJIaC1qNkZuOEE4NGhEeWVxeEp2ZDgxUk9DOU9udmJUdDdGcnpkRVo0YmJ6QTFCLVl6ZUlGTzhVQQ?oc=5","date":"2023-11-27","type":"pipeline","source":"White & Case LLP","summary":"White & Case Advises Athyrium Capital Management on the Restructuring of RevitaLid Pharmaceutical Corp. and its Subsidiaries - White & Case LLP","headline":"White & Case Advises Athyrium Capital Management on the Restructuring of RevitaLid Pharmaceutical Corp. and its Subsidia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPclpkRm5WeXJBYWtRdEtXbzY1Y0JrUU02TkVGZ25iVWtIMFVOSG9JRG1seVdHRC1GeHluVWFPaHd3S3RzOFFQYTdXUUJUUDJCREhFLUtPRW5CZWVkTUtGZUx1TVc0MS00Z094NGNFNGpVOXJCb0NUNEVwTm1lNk00Q3Y0MVl3aTNlOWViUmVtTzN3c204NE1qcW9JVGZReTZFblJtc0NFTmFwM1VKaVE?oc=5","date":"2023-11-27","type":"pipeline","source":"GlobeNewswire","summary":"RVL Completes Financial Restructuring - GlobeNewswire","headline":"RVL Completes Financial Restructuring","sentiment":"neutral"},{"date":"2023-11-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-10-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-10-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxPd2tJd2dLbUdycWl5LU1IMDVpeGtFN2ExNndudTFjWks5SGJjaW56ampkYVgwTzVwSUdZTWl2RkdWOWRjR2tzX19vTFRsUzVqMjdKcll4a29pNGtQTmdoRnRMVFVsMF94UWYtVV9fekVfbnVxY2kzNS11RUkteTlDSTNzVlNJdWtKMTlyR2RtVlVuZkZWMFNRSGhKVkxHNHFUbDhmOHl3aDhHUGdJVkZhMjkxdWVWODNZTFhzMVdjam5KZmh0WWpEWHZqRDZVM1psUFd5UGh4ZGlDYmdkX2FPQWxJdlhnTHdNZlpCTGtlQ0lVQQ?oc=5","date":"2023-10-12","type":"pipeline","source":"GlobeNewswire","summary":"RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries - GlobeNewswire","headline":"RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries","sentiment":"neutral"},{"date":"2023-09-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxQQUUwdUZKT1gwRVJzbHNlRXM3bThRS0tlQU1FSzNJMlJYbWVKUjdqdjBzNHlvV2dUYUdXaUh2OTB6MGdrOEZOM083SnNfUkltZUlvSkU1azV4djhXbGRHZTQxbThDczNySnlqdjUtNjdmZk5FR2RoS0JGdF91V3BRMWxPWHZ0bTRFM2ZGeEs4WkdVN2RCVkNqdUkxZ1dJMjJ4RXEtRDFxU1dienhleVZvcWl5c2tiN0Qwdll6aVgyWGZuWTUyRG83OXdoSTJMbmpkdjJGRUtzRlpCWHc0eE1XSTNBN19iYnI4Y1BDV0o5V1d6U1o2cy01V3N0c3p5V0ZCZGpHYmZhUDh6WkY0SndR?oc=5","date":"2023-08-16","type":"pipeline","source":"GlobeNewswire","summary":"RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules - GlobeNewswire","headline":"RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQeFhMZHhVWllEc1p6a01qMjdiclZvbk5aYzBYeWFuSTFqTFczR1l0N1M4ODNlWUxwSkRLNEtKc0VTV3VBcUlwTFdBRXg1Nmg1d3dMWWx0YWpGcjFHUUNZVjVmcnZFLVNxX3RERGlIWGVJX09EdTViZmM2bnhFRGhjRDhZN1g1b2dnNXByYXZlZkM?oc=5","date":"2023-04-03","type":"pipeline","source":"Yahoo Finance","summary":"RVL Pharmaceuticals Announces that Upneeq® Wins “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty Awards - Yahoo Finance","headline":"RVL Pharmaceuticals Announces that Upneeq® Wins “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty Awards","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOMVRLdGttM1I0bmd5WC1JYlNxMWZuNFVaZnJMZGhXZGZhay05aGJ3R3VWSFBTblEwUmRrVG5rcWtjdzE3em9SbkRwNWg3TFRMVWgzcDVvV3dlR1MxYjVYZ3Y1UlhXN2NidVV2aU5TN0NzSXFJSng3U3NsRkkzWnVVWktyT2JPck9rbjBORkdJRE5IT2pqTmNQc2xkN1F4UlprdklKOHJvdy1tRHExRFQ3X212bDhscUZNMXhlbkRSV3BVODkteVJWN2VNOXZ2ZHRxRGVXd1FpV2xrejNxdzVQMFlLQjFIV2JDZUE?oc=5","date":"2022-07-07","type":"earnings","source":"PR Newswire","summary":"RVL Pharmaceuticals plc Announces Preliminary Second Quarter 2022 UPNEEQ® Net Product Sales Results - PR Newswire","headline":"RVL Pharmaceuticals plc Announces Preliminary Second Quarter 2022 UPNEEQ® Net Product Sales Results","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":49721000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":49721000,"period":"2022-12-31"},{"value":17501000,"period":"2021-12-31"},{"value":177884000,"period":"2020-12-31"},{"value":240031000,"period":"2019-12-31"},{"value":263701349,"period":"2018-12-31"},{"value":245749032,"period":"2017-12-31"}],"grossProfit":40265000,"grossProfitHistory":[],"rdSpend":3966000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-51692000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":128510000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}